Novo Nordisk A/S: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Novo Nordisk's performance against key rivals in the prescription pharmaceutical sector

*Assess the company's highly focused strategy, centred on the use of therapeutic proteins and internally sourced R&D

*Analyze how Novo Nordisk's dominance in the diabetes market will elevate the company to the Big Pharma peer set by 2010

Report Highlights

[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002–14 6
Financial performance, 2002–14 7
Novo Nordisk: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 12
Chapter 3 Quarterly news update 22
Quarterly sales update, Q2 2009 22
Product developments 22
Deals and alliances 23
M&A activity 24
Company announcements 24
Future product milestones 25
Chapter 4 Company introduction 26
Key findings 26
Background 27
Key corporate developments 27
M&A history 28
Current corporate structure 30
Chapter 5 Company sales 32
Key findings 32
Prescription pharmaceutical sales and growth rate analysis, 2002–14 33
Product analysis 35
Therapy area analysis 43
Geographic analysis 46
Launch/core/expiry analysis 49
Molecule type analysis 56
Externalization analysis 59
Chapter 6 Company financials 61
Key findings 61
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002–08 62
Operating costs and profit analysis 63
Chapter 7 Key products and competitors 69
Key findings 69
Overview 70
Diabetes market overview 71
Endocrine, metabolic & genetic disorders 77
Hematology 94
Chapter 8 Appendix 97
R&D pipeline 97
References 98
Abbreviations 98
Exchange rates 100
About Datamonitor 101
Datamonitor consulting 101
Disclaimer 103
[Inhaltsverzeichnis ausblenden]

TABLES
Table 1: Novo Nordisk – PharmaVitae forecasts at a glance 8
Table 2: Novo Nordisk key product developments, 2009 22
Table 3: Novo Nordisk product deals and alliances, 2009 23
Table 4: Novo Nordisk technology deals and alliances, 2009 23
Table 5: Novo Nordisk M&A activity, 2009 24
Table 6: Novo Nordisk company announcements, 2009 24
Table 7: Novo Nordisk future product milestones, 2009–11 25
Table 8: Novo Nordisk product portfolio overview ($m), 2002–08 36
Table 9: Novo Nordisk product portfolio overview ($m), 2008–14 39
Table 10: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2008–14 44
Table 11: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2008–14 47
Table 12: Novo Nordisk launch portfolio overview ($m), 2008–14 50
Table 13: Novo Nordisk core portfolio overview ($m), 2008–14 52
Table 14: Novo Nordisk expiry portfolio overview ($m), 2008–14 53
Table 15: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2008–14 57
Table 16: Novo Nordisk prescription pharmaceutical sales by source ($m), 2008–14 60
Table 17: Total Novo Nordisk sales by business unit ($m), 2002–08 62
Table 18: Novo Nordisk operating revenue/cost analysis ($m), 2002–08 64
Table 19: Novo Nordisk operating cost ratio analysis (% of total revenues), 2002–08 66
Table 20: Novo Nordisk operating cost ratio analysis (% of total revenues), 2008–14 67
Table 21: Novo Nordisk operating revenue/cost analysis ($m), 2008–14 68
Table 22: Key products overview 70
Table 23: Key insulin antidiabetics in 2008 74
Table 24: Key non-insulin antidiabetics in 2008 75
Table 25: NovoRapid: overview 77
Table 26: NovoRapid: sales forecast ($m), 2008–14 78
Table 27: NovoMix: overview 80
Table 28: NovoMix: sales forecast ($m), 2008–14 81
Table 29: Levemir: overview 83
Table 30: Levemir: sales forecast ($m), 2008–14 84
Table 31: Actraphane: overview 86
Table 32: Actraphane: sales forecast ($m), 2008–14 87
Table 33: Victoza: overview 88
Table 34: Victoza: sales forecast ($m), 2008–14 89
Table 35: Norditropin: overview 92
Table 36: Norditropin: sales forecast ($m), 2008–14 93
Table 37: NovoSeven: overview 94
Table 38: NovoSeven: sales forecast ($m), 2008–14 95
Table 39: Key hemophilia products in 2008 95
Table 40: Novo Nordisk’s R&D pipeline (Phase I–registration) 97
Table 41: Exchange rates, 2009 100
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002–14 6
Figure 3: Novo Nordisk’s financial performance ($m), 2002–14 7
Figure 4: Novo Nordisk presence in its key target markets (% of total market revenue), 2002–14 9
Figure 5: Novo Nordisk SWOT analysis 12
Figure 6: Novo Nordisk corporate history 27
Figure 7: Novo Nordisk corporate structure 30
Figure 8: Pharmaceuticals business unit structure, % of total annual revenue 31
Figure 9: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002–14 33
Figure 10: Key product sales ($m), 2002–14 35
Figure 11: Novo Nordisk key sales growth drivers and resistors ($m), 2002–08 37
Figure 12: Novo Nordisk key sales growth drivers and resistors ($m), 2008–14 40
Figure 13: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2002–14 43
Figure 14: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2002–14 46
Figure 15: Novo Nordisk launch/core/expiry configuration ($m), 2008–14 55
Figure 16: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2002–14 56
Figure 17: Novo Nordisk prescription pharmaceutical sales by source ($m), 2002–14 59
Figure 18: Novo Nordisk operating revenue/cost analysis ($m), 2002–14 63
Figure 19: Key competitors to Novo Nordisk in the antidiabetics market 73
[Tabellenverzeichnis ausblenden]